»  Búsqueda

 


Búsqueda avanzada



»  Newsletter

Subscribe to our e-mail newsletter to get our latest news and dates by e-mail


Subscribe / Unsubscribe



31/08/2009

Company Event on Friday, September 4th 2009!



17/07/2009

BRAHMS KRYPTOR compact is certified by the Fetal Medicine Foundation (FMF)

Hennigsdorf, Germany, 16-07-2009. The Fetal Medicine Foundation (FMF) confirmed that BRAHMS KRYPTOR compact is fulfilling the requirements for first trimester biochemical screening.

02/07/2009

New Cardiac Marker Copeptin accelerates Diagnosis of Acute Myocardial Infarction (AMI)

Hennigsdorf, July 2, 2009. The novel biomarker Copeptin can improve patient management in the Emergency Department (ED). The study “Incremental Value of Copeptin for Rapid Rule Out of Acute Myocardial Infarction (AMI)” was recently published in the Journal of the American College of Cardiology (JACC).

28/05/2009

B·R·A·H·M·S Iberia S.L. comienza su actividad en España

B·R·A·H·M·S Aktiengesellschaft se complace en anunciarle la incorporación de su filial Española, denominada BRAHMS Iberia, S.L.

19/12/2008

INTRODUCCIÓN EN EL MERCADO DE UN NUEVO PRODUCTO DE DIAGNÓSTICO (SCREENING) PRENATAL: Software B·R·A·H·M·S Fast Screen pre II

Nos complace anunciar el lanzamiento del nuevo producto de B·R·A·H·M·S con marca CE. B·R·A·H·M·S Fast Screen pre II es un software para el cálculo del riesgo individual de síndrome de Down (trisomía 21), el síndrome de Edward (trisomía 18), y defectos del tubo neural (DTN) del feto en el segundo trimestre de embarazo (edad gestacional 14+0 a 19+6).

13/11/2008

B·R·A·H·M·S Announces New Blood Test Better Predicts Heart Failure Outcomes in Emergency Setting

Data Presented in a Late Breaker Presentation at AHA Shows MR-proADM Surpasses Industry Standard

01/09/2008

New biomarkers: Substantial success in the improvement of diagnosis of patients suffering from shortness of breath

BACH study shows that MR-proANP adds additional information on standard of care in the diagnosis of acute congestive heart failure. The use of PCT together with MR-proANP supports the differential diagnosis of pneumonia and congestive heart failure.

02/06/2008

B·R·A·H·M·S AKTIENGESELLSCHAFT y DIASORIN S.P.A. firman un nuevo acuerdo de licencia sobre el ENSAYO DE PROCALCITONINA (PCT)

B·R·A·H·M·S AKTIENGESELLSCHAFT y DIASORIN S.P.A. firman un nuevo acuerdo de licencia sobre el ENSAYO DE PROCALCITONINA (PCT) para las PLATAFORMAS DE INMUNOANÁLISIS LIAISON DE DIASORIN


Página : 2